ReviewFrontiers in oncology2019
O
Review in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
153 citing papers in PubMed, 6 syntheses or guidelines pooled it, 249 citations in OpenAlex.
- Diagnostic Accuracy of Artificial Intelligence for Predicting MGMT Promoter Methylation in Glioblastoma Using MR Imaging: A Systematic Review.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026Pooled it
- Critical regulatory roles of non-coding RNAs in driving cancer sensitivity to Carmustine: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- AI-driven estimation of O6 methylguanine-DNA-methyltransferase (MGMT) promoter methylation in glioblastoma patients: a systematic review with bias analysis.Journal of cancer research and clinical oncology · 2024Pooled it
- Dietary Factors and Risk of Glioma in Adults: A Systematic Review and Dose-Response Meta-Analysis of Observational Studies.Frontiers in nutrition · 2022Pooled it
- The effect of levetiracetam treatment on survival in patients with glioblastoma: a systematic review and meta-analysis.Journal of neuro-oncology · 2022Pooled it
- Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.Pharmacological research · 2021Pooled it
- MGMT promoter methylation as a molecular biomarker in neuro-oncology: current practices, challenges, and future directions.Journal of neuro-oncology · 2026Review
- Exploring the Role of DNA Methylation in the Epigenetic Landscape of Cancer.Biochemical genetics · 2026Review
- Autophagy as a therapeutic target for cisplatin-resistant gastric cancer.Genes & diseases · 2026Review
- Decoding and Overcoming Temozolomide Resistance Through CRISPR/Cas Technologies.Molecular diagnosis & therapy · 2026Review
- Radiogenomics for Glioblastoma Survival Prediction: Integrating Radiomics, Clinical, and Genomic Features Using Artificial Intelligence.Journal of imaging informatics in medicine · 2026Article
- MGMT promoter methylation across glioma subtypes: biological relevance, treatment response, and survival outcomes.Molecular biology reports · 2026Review
- Quiescent neural stem cells transiently become neuron-like to coordinate long-range reactivation.The EMBO journal · 2026Article
- Correlation Between 1p19q Status and Various Biomarkers in Selected Central Nervous System Tumors.Cureus · 2026Article
- Molecular Links Between Smoking, COPD, and Lung Cancer: A DNA Methylation Perspective.Cancers · 2026Article
- Epigenetic Alterations in Microbiome-Host Interactions in Inflammatory and Autoimmune Diseases.International journal of molecular sciences · 2026Review
- E3 ligase LMO7 enhances temozolomide sensitivity by promoting MGMT degradation in lung cancer.The Journal of biological chemistry · 2026Article
- Exploiting Methyl Triazenes as Attractive Alternatives to Temozolomide and Dacarbazine for Cancer Therapy.Molecules (Basel, Switzerland) · 2026Review
- Cannabidiol as a Prophylactic Agent Against Glioblastoma Growth: A Preclinical Investigation.International journal of molecular sciences · 2026Article
- Targeting glioblastoma multiforme with Demethoxycurcumin and its analogues: current evidence and future directions.Molecular biology reports · 2026Review
93 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemoresistance has been a significant problem affecting the efficacy of drugs targeting tumors for decades. MGMT, known as O
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.